Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis

Aim: We performed a systematic review and network meta-analysis evaluating the safety and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among dialysis chronic kidney disease patients.Methods: Safety was evaluated with any adverse events (AEs), serious adverse events (...

Full description

Bibliographic Details
Main Authors:	Dinghua Chen, Yue Niu, Fei Liu, Yue Yang, Xue Wang, Ping Li, Xiangmei Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Pharmacology
Subjects:	hypoxia-inducible factor prolyl hydroxylase inhibitors chronic kidney disease anemia renal dialysis adverse event erythropoiesis-stimulating agent
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1163908/full

Similar Items

Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
by: Junlan Yang, et al.
Published: (2023-03-01)

Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors
by: Akira Takahashi
Published: (2024-02-01)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020-07-01)

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
by: Matthew E Cockman, et al.
Published: (2019-09-01)

Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study
by: Kimio Watanabe, et al.
Published: (2023-08-01)

Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure
by: Mayu Yazaki, et al.
Published: (2024-01-01)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023-11-01)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
by: Hanxue Zhao, et al.
Published: (2023-12-01)

Network activity in primary hippocampal cultures upon HIF-prolyl hydroxylase inhibition
by: Savyuk, Maria Olegovna, et al.
Published: (2021-05-01)

Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease
by: Mrittika Roy, et al.
Published: (2023-12-01)

Research progress on treatment of renal anemia in patients with chronic kidney disease
by: Li Yudong, Liao Wenjian, Luo Yonghang, Chen Qiuyu, Su Yong
Published: (2023-05-01)

Structural Characterization of Hypoxia Inducible Factor α—Prolyl Hydroxylase Domain 2 Interaction through MD Simulations
by: Giorgia F. Camagni, et al.
Published: (2023-03-01)

Prolyl Hydroxylase 3 Knockdown Accelerates <i>VHL</i>-Mutant Kidney Cancer Growth In Vivo
by: Niki M. Zacharias, et al.
Published: (2021-03-01)

Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report
by: Nobuaki Ariyoshi, et al.
Published: (2024-03-01)

An Arabidopsis Prolyl 4 Hydroxylase Is Involved in the Low Oxygen Response
by: Anna Konkina, et al.
Published: (2021-03-01)

Role of prolyl hydroxylase domain proteins in bone metabolism
by: David Wolf, et al.
Published: (2022-03-01)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
by: Jie Lun, et al.
Published: (2023-05-01)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
by: Li Zheng, et al.
Published: (2022-09-01)

Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients
by: Ya-Hui Yang, et al.
Published: (2023-12-01)

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study
by: Xuejie Zhang, et al.
Published: (2023-11-01)

Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
by: Jose Portolés, et al.
Published: (2021-03-01)

HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury
by: Andrew N. Billin, et al.
Published: (2018-11-01)

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study
by: Yudian Wang, et al.
Published: (2024-01-01)

Prolyl hydroxylase inhibitor FG-4592 alleviates neuroinflammation via HIF-1/BNIP3 signaling in microglia
by: Qianqian Ruan, et al.
Published: (2024-04-01)

Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases
by: Satoshi Yamasaki, et al.
Published: (2023-03-01)

Aspectos no resueltos en el manejo de la anemia renal, un consenso Delphi del Grupo de Anemia de la S.E.N
by: José Portolés, et al.
Published: (2023-09-01)

Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer
by: Helge Waldum
Published: (2023-06-01)

Whole-Body Prolyl Hydroxylase Domain (PHD) 3 Deficiency Increased Plasma Lipids and Hematocrit Without Impacting Plaque Size in Low-Density Lipoprotein Receptor Knockout Mice
by: Jasper A. F. Demandt, et al.
Published: (2021-05-01)

Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats
by: Anqi Zhang, et al.
Published: (2021-06-01)

Research progress on roxadustat treatment for renal anemia
by: HU Bao-li, HU Bin
Published: (2022-09-01)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
by: Chintala Sreenivasulu, et al.
Published: (2012-07-01)

MYC overrides HIF-1α to regulate proliferating primary cell metabolism in hypoxia
by: Courtney A Copeland, et al.
Published: (2023-07-01)

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
by: Limei Xiong, et al.
Published: (2022-01-01)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
by: Ishii T, et al.
Published: (2021-02-01)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
by: Keiji Hirai, et al.
Published: (2021-07-01)

Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice
by: Shunji Nishide, et al.
Published: (2020-06-01)

Long-Term Environmental Hypoxia Exposure and Haematopoietic Prolyl Hydroxylase-1 Deletion Do Not Impact Experimental Crohn’s Like Ileitis
by: Cara De Galan, et al.
Published: (2021-09-01)

miR‐17/20 Controls Prolyl Hydroxylase 2 (PHD2)/Hypoxia‐Inducible Factor 1 (HIF1) to Regulate Pulmonary Artery Smooth Muscle Cell Proliferation
by: Tianji Chen, et al.
Published: (2016-12-01)

Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis
by: Qiyan Zheng, et al.
Published: (2023-04-01)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
by: So Yeon Kim, et al.
Published: (2015-11-01)